

Ethnopharmaceuticals for the Treatment of Old World Cutaneous Leishmaniasis: A systematic review of topical application of Turmeric




Privanka Challa¹, Ruwandi Kariyawasam², Eric Shao³, Jason Kwan⁴, Tianna Chong-Kit⁵, Anjola Ogunsina⁶, Shveta Bhasker⁷, Sonia Igboanugo⁸, Hira Raheel⁹, Shareese Clarke¹⁰, Mofe Adeosun¹¹, Emma Hagopian², Paul Dunn¹⁰, Olamide Egbewumi¹¹, Avinash Mukkala¹, Swana Kopalakrishnan^{12,} David Harris¹³, Andrea K. Boggild^{1,9,13}

¹Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ²Institute of Medical Science, University of Toronto, ON, Canada, ³Department of Microbiology and Immunology, University of Western Ontario, London, ON, Canada, ³Department of Microbiology and Immunology, University of Western Ontario, London, ON, Canada, ⁴Institute of Medical Science, University of Toronto, Toronto, ON, Canada, ⁴Institute of Medical Science, University of Toronto, ON, Canada, ⁴Institute of Medical Science, University of Toronto, Toronto, ON, Canada, ⁴Institute of Medical Science, University of Toronto, ON, Canada, ⁴Institute of Medical Science, University of Toronto, Toronto, ON, Canada, ⁴Institute of Medical Science, University of Toronto, ON, Canada, ⁴Institute of Medical Science, University of Toronto, ON, Canada, ⁴Institute of Medical Science, University of Toronto, ON, Canada, ⁴Institute of Medical Science, University of Toronto, ON, Canada, ⁴Institute of Medical Science, University of Toronto, ON, Canada, ⁴Institute of Medical Science, University of Toronto, ON, Canada, ⁴Institute of Medical Science, University of Toronto, ON, Canada, ⁴Institute of Medical Science, University of Toronto, ON, Canada, ⁴Institute of Medical Science, University of Toronto, ON, Canada, ⁴Institute of Medical Science, University of Toronto, ON, Canada, ⁴Institute of Medical Science, University of Toronto, ON, Canada, ⁴Institute of Medical Science, University of Toronto, ON, Canada, ⁴Institute of Medical Science, University of Toronto, ON, Canada, ⁴Institute of Medical Science, University of Toronto, ON, Canada, ⁴Institute of Medical Science, University of Toronto, ON, Canada, ⁴Institute of Medical Science, University of Toronto, ON, Canada, ⁴Institute of Medical Science, University of Toronto, ON, Canada, ⁴Institute of Medical Science, University of Toronto, ON, Canada, ⁴Institute of Medical Science, University of Toronto, ON, Canada, ⁴Institute of Medical Science, Universit ⁴Department of Health Sciences, McMaster University, Hamilton, ON, Canada, ⁵Department of Biochemistry, University of Waterloo, ON, Canada, ⁶Department of Life Science, Queen's University, Kingston, ON, Canada, ⁷Department of Psychology, University of Toronto Mississauga, Mississauga, ON, Canada, ⁸Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada, ⁹Department of Medicine, University of Toronto, Toronto, ON, Canada, ¹⁰Faculty of Health Sciences, University of Ontario Institute of Technology, Toronto, ON, Canada, ¹¹Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ¹⁰Faculty of Health Sciences, University of Ontario Institute of Technology, Toronto, ON, Canada, ¹¹Dalla Lana School of Public Health, University of Toronto, ON, Canada, ¹⁰Faculty of Health Sciences, University of Ontario Institute of Technology, Toronto, ON, Canada, ¹¹Dalla Lana School of Public Health, University of Toronto, ON, Canada, ¹⁰Faculty of Health Sciences, University of Ontario Institute of Technology, Toronto, ON, Canada, ¹¹Dalla Lana School of Public Health, University of Toronto, ON, Canada, ¹⁰Faculty of Health Sciences, University of Ontario Institute of Technology, Toronto, ON, Canada, ¹¹Dalla Lana School of Public Health, University of Toronto, ON, Canada, ¹⁰Faculty of Health Sciences, University of Ontario Institute of Technology, Toronto, ON, Canada, ¹¹Dalla Lana School of Public Health, University of Toronto, ON, Canada, ¹⁰Faculty of Health Sciences, University of Ontario Institute of Technology, Toronto, ON, Canada, ¹¹Dalla Lana School of Public Health, University of Toronto, ON, Canada, ¹⁰Faculty of Health Sciences, University of Ontario Institute of Technology, Toronto, ON, Canada, ¹⁰Faculty of Health Sciences, University of Ontario Institute of Technology, Toronto, ON, Canada, ¹⁰Faculty of Health Sciences, University of Ontario Institute of Technology, Toronto, ON, Canada, ¹⁰Faculty of Health Sciences, University of Ontario Institute of Technology, Toronto, ON, Canada, ¹⁰Faculty, ¹⁰

¹¹Department of Biology, Faculty of Sciences, McMaster University, Hamilton, ON, Canada, ¹²School of Medicine, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada, ¹³Tropical Disease Unit, UHN-Toronto General Hospital, Toronto, ON, Canada

Introduction

- Toxicity, expense, and accessibility limit treatment success in cutaneous leishmaniasis (CL), a neglected parasitic disease caused by members of the genus Leishmania.¹
- Old World Cutaneous Leishmaniasis (OWCL) is widespread in the Middle East, the Mediterranean, Arabian Peninsula, Africa and the Indian Subcontinent.
- OWCL is caused due to L. major, L. tropica, L. aethiopica, L. infantum, and L. donovani.
- High toxicity and ineffective treatment management of current drugs warrants the development of novel medications with better health and risk ratio
- Ethnopharmaceuticals are plant-based compounds with potential anti- leishmanial effects found in and around local endemic communities²



- *infantum* (53, 20%), *L. tropica* (24, 9%), and *L. aethiopica* (4, 2%) (Figure 1& 2).
- the control (Table 1)
- that has not seen any new drug development for over half a century.

1. World Health Organization (2010). Control of the leishmaniases. World Health Organization Technical Report Series, (949), 22–26. https://doi.org/10.1038/nmicro1766. American Journal of Ethnomedicine. Retrieved October 23, 2018. 2. Guyatt G,Oxman AD, Akl EA, Kunz R, Vist G, Brozek , Norris S, Falck-Ytter Y, Glasziou P, Jaeschke R, Rind D, Meerpohl , Dahm P, Schunemann HIGRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings table. Clin Epidemiol 2011; 64(4):380-2. 3. Fouladvand, M., Barazeshi, A., Tahasebi, R. Evaluation of in vitro antileishmanial activity of curcumin and its derivatives "Gallium curcumin, Indium curcumin". European Review for Medical and Pharmacological Sciences 2013; 17:3306-3308. 4. Salheen, D., Ali, S.A., Ashaq, K., Siddiqui, A.A., Agha, A., Yasinazai, M. M. Latent Activity of Curcumin against Leishmaniasis in Vitro. Biol. Pharm. Bull. 2002;25(386-389). 5. Koide, T, Nose, M., Ogihara, Y., Yabu, Y., Ohta, N. Leishmanicidal Effect of Curcumin in Vitro. Biol. Pharm. Bull 2002; 25:131-133. 6. Chan, M., Adpala, N.S., Fong, D. Curcumin overcomes the inhibitory effect of nitric oxide on Leishmania. Parasitol Res 2005; 96:49-56. [DOI: 10.1007/s00436-005-1323-9] 7. Changtam, C., P. de Koning, H., Ibrahim, H., M. Sohail Sajid, Matthew K. Gould, Apichart Suksamran. Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species. European Journal of Medicinal Chemistry 2010; 45:941–956. [DOI: 10.1016/j.ejmech.2009.11.035] 8. Cheikh-Ali, Z., Caron, J., Cojean, S., Bories, C., Couvreur, P., Loiseau, P., Poupon, D.D., Pierre Champy, E. "Squalenoylcurcumin" Nanoassemblies as Water- Dispersible Drug Candidates with Antileishmanial Activity. ChemMedChem 2015;10:411-418. [DOI: 10.1002/cmdc.201402449]

Results

• 2320 abstracts were found using the GRADE approach from 1957-present. Of the 260 abstracts pertaining to Old World, *Curcuma* spp. "Turmeric" was identified in 6 articles (2%), to date (Figure 1) • 551 abstracts met inclusion criteria for full-text review, of which, 260 (47%) abstracts pertained to Old World species, and 113/260 (21%) were specific to L. donovani, followed by L. major (66, 25%), L.

• In the 6 full-text articles, 4 Old World CL species were prevalent: L. major (5, 83%), L. donovani (2,33%), L. tropica (1, 17%), and L. infantum (1, 17%) (Figure 3) • Two, in-vitro studies to date have compared the effects of curcumin against standardized treatments (pentamidine and amphotericin B) in which, curcumin, in higher concentrations, yielded greater potency than

Conclusion

• Synthesizing the current evidence surrounding ethnopharmaceuticals for the treatment of OWCL may contribute to drug discovery pipelines and potentially lead to novel therapeutics in a field

References

Objective

We aim to synthesize existing evidence around available ethnopharmaceuticals to promote drug discovery for the treatment of OWCL

Methods


PubMed (NCBI), Medline (OVID), Embase (OVID), Web of Science (BioSIS) and LILACS (VHL) were searched from inception to October 31, 2019 using combinations of the search terms "cutaneous leishmaniasis" "ethnopharmaceuticals", "botanical", "plant derived", "curcumin", and "turmeric"

Systematic review includes molecular, mechanistic, and observational studies, case reports, case series, cohort studies, as well as clinical trials reporting therapeutic outcomes, if possible

stribution in abstracts			Old World Cl
ntum 🗧 L. tropica 🔳 L. aethiopica			L. major
valent in abstracts		ure 3 : OwcL Irmeric"	species distribution
mpounds against OWCL in <i>vitro</i>			
entration drugs (curcumin and pentamidine) in culture medium of L.	OWCL species		Main outcome The leishmaniacidal
)	Promastigotes L. tropica, L.in major		higher potency in vit
tions of curcumin dissolved in dimethyl suloxide (DMSO) well and incubated at 27°C. The leishmanicidal activity of wn as 50% growth inhibitory (GI ₅₀), 100% growth inhibitory) and LD ₅₀ after incubation with leishmania for 24h.	Promastigotes: <i>L. major</i>		Curcumin demonstra
ion) added at different concentrations to the cultures	Promastigotes: <i>L. major, L. donovani</i>		At a range from 5 m major Curcumin concentra
oxycurcumin, and bisdemethoxycurcumin were chemically logs and 8 pairs of 1:1 mixture of curcuminoid analogs	Promastigotes: <i>L. major</i>		Parent and analog control of Among the active and L. major promastigor
curcumin, indium curcumin, and diacetylcurcumin vs.	Promastigotes: <i>L. major</i>		Indium curcumin wa diacethyle curcumin 5µg/ml for all, IC50:

Promastigotes:


L. donovani



Toronto General Toronto Western Princess Margaret Toronto Rehab

Public Health

PARTNERS FOR HE



Website: <u>www.boggildlab.ca</u>